Press Releases
2010
January
January
01/28/2010Cepheid Reports Fourth Quarter and Full Year 2009 Results
01/14/2010
Cepheid Schedules 2009 Fourth Quarter and Full Year Financial Results Announcement and Webcast
01/06/2010
Cepheid Receives FDA Clearance for First Rapid and Accurate Surveillance Test for vanA -- the Resistance Gene Most Associated with Hospital-Acquired VRE Infections
01/05/2010
Cepheid to Webcast Upcoming Financial Presentation
01/04/2010
Cepheid Receives FDA Emergency Use Authorization (EUA) for First 2009 H1N1 Influenza Assay for CLIA 'Moderate Complexity' Laboratories
2009
November
11/05/2009Cepheid to Webcast Upcoming Financial Presentations
October
10/28/2009Cepheid Reports 2009 Third Quarter Results
10/13/2009
Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast
10/13/2009
Cepheid Expands Leadership Team With Appointment of Executive Vice President of Worldwide Commercial Operations
September
09/24/2009Cepheid Receives FDA Clearance for Xpert(R) HemosIL(R) FII & FV Test
09/09/2009
Cepheid Announces Accelerated Development of Flu A Panel Test
August
08/26/2009Cepheid to Webcast Upcoming Financial Presentations
July
07/30/2009Cepheid Reports 2009 Second Quarter Results
07/13/2009
Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection
07/09/2009
Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast
June
06/24/2009New England Journal of Medicine Study Highlights Need for Rapid, PCR-based Group B Streptococcus (GBS) Testing at Time of Admission for Labor and Delivery
06/17/2009
Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML)
06/10/2009
Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System
06/04/2009
Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control (APIC) Annual Conference
06/03/2009
Cepheid Receives Health Canada License for Xpert(R) HemosIL(R) FII & FV Test
April
04/30/2009Cepheid to Webcast Upcoming Financial Presentations
04/28/2009
Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
04/27/2009
Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin
04/23/2009
Cepheid Reports 2009 First Quarter Results
04/09/2009
Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast
March
03/31/2009Cepheid Announces European Release of First On-Demand Molecular Pre-Surgical Screening Test for Simultaneous Detection of Methicillin-Sensitive and Resistant S. aureus
03/24/2009
Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB)
03/11/2009
Cepheid Receives Health Canada License for First On-demand Diagnostic Test for Life-threatening MRSA and S. aureus Infections From Patient Positive Blood Culture Bottles
February
02/05/2009Cepheid Reports Fourth Quarter and Full Year 2008 Results
January
01/13/2009Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
2008
December
12/04/2008Cepheid to Webcast Upcoming Financial Presentations
November
11/24/2008Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections
11/10/2008
Cepheid Launches First On-Demand Molecular Diagnostic Test for Clostridium Difficile Into European Market
11/07/2008
Cepheid to Webcast Upcoming Financial Presentations
11/04/2008
Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA
11/03/2008
Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific
October
10/28/2008Cepheid Reports Third Quarter Revenue of $44.9 Million
10/27/2008
Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
10/15/2008
Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized 'Moderate Complexity' by FDA
10/07/2008
Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection
10/03/2008
Cepheid Schedules Fiscal 2008 Third Quarter Financial Results Announcement and Webcast
10/01/2008
Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
September
09/29/2008Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
09/26/2008
California Legislation Highlights Need for Broad Menu of Tests in Growing Healthcare Acquired Infection Market
August
08/22/2008Cepheid to Webcast Upcoming Financial Presentations
July
07/29/2008Cepheid Introduces GeneXpert(R) Infinity-48 System at 2008 American Association of Clinical Chemistry Meeting
07/28/2008
Cepheid GeneXpert(R) System and Xpert(TM) MRSA Selected for up to 11 Victoria, Australia Hospitals in Rollout of 'Start Clean' Strategy
07/24/2008
Cepheid Reports Second Quarter Revenue of $42.1 Million
07/21/2008
Cepheid to Webcast Analyst Event
07/14/2008
Cepheid Schedules Fiscal 2008 Second Quarter Financial Results Announcement and Webcast
07/09/2008
Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program
June
06/04/2008Cepheid Management to Present at the 7th Annual Needham Medical Technology and Biotechnology Conference and William Blair's 28th Annual Growth Stock Conference
06/03/2008
Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico
May
05/20/2008Cepheid Signs Group Purchasing Contract with Novation, the Nation's Largest Healthcare Contracting Organization
05/12/2008
Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations
05/06/2008
Cepheid to Present at the Robert W. Baird Growth Stock Conference and the Bank of America Healthcare Conference
05/01/2008
Cepheid Reports Record Revenue of $44.8 Million
April
04/07/2008Cepheid Schedules Teleconference and Webcast for First Quarter 2008 Results
04/03/2008
Cepheid Selected as Vendor of Choice by Connecticut Hospital Association Shared Services Program for Molecular MRSA Surveillance Testing
March
03/12/2008Cepheid Comments on Study Regarding MRSA Surveillance Reported in the Journal of the American Medical Association
03/10/2008
Cepheid to Present at Cowen and Company's 28th Annual Healthcare Conference
February
02/28/2008Cepheid Reports Fourth Quarter and Full Year 2007 Results
02/25/2008
Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
02/11/2008
Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
02/06/2008
Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
January
01/29/2008Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System